SG&A at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s SG&A?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported SG&A of $16.17M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s SG&A increased by 3.1% year-over-year, from $15.68M to $16.17M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s SG&A has grown at a -20.9% compound annual growth rate (CAGR), from $127.13M to $62.89M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.